Waters Corporation Unveils BioResolve Protein A Affinity Columns to Enhance Antibody Measurement Efficiency
Introduction
The landscape of biopharmaceuticals is rapidly evolving, and in this dynamic environment, early and accurate measurement of antibody titers is critical. In light of this, Waters Corporation has officially launched its innovative BioResolve™ Protein A Affinity Columns featuring MaxPeak™ Premier technology. This highly anticipated product marks a significant debut for Waters, enhancing bioprocess efficiency and ultimately facilitating faster therapeutic delivery.
Key Features of BioResolve Columns
The BioResolve Protein A Affinity Columns are designed to revolutionize antibody titer measurement. Here’s what sets them apart:
1. Enhanced Sensitivity
These new affinity columns boast a revolutionary design that ensures up to seven times greater sensitivity compared to existing market leaders. Thanks to their non-porous 3.5 µm particles, they enable precise quantification of antibody titers at greatly reduced concentrations, allowing researchers to work with less sample material.
2. Faster Results
One of the most impressive advantages of the BioResolve columns is their ability to shorten the time needed for vital results. By expediting the measurement processes, these columns can deliver antibody titer results up to two days earlier, which can significantly streamline the selection process for clones and control over bioprocesses.
3. Multi-Attribute Analysis Integration
The design of BioResolve facilitates simultaneous multi-attribute workflows. This feature allows scientists to evaluate multiple critical quality attributes (CQAs) in one pass, significantly optimizing laboratory operations. For instance, integrating size-exclusion chromatography helps in assessing aggregate analysis alongside titer measurement.
A Shift Towards Better Biotherapeutics
Dr. Udit Batra, President and CEO of Waters Corporation, emphasized the impact of this innovation on biotherapeutic development, stating, “The challenge of finding and optimizing an appropriate cell line for monoclonal antibody production can be incredibly time-consuming. Our enhanced columns address this issue by providing advanced particle technology combined with MaxPeak Premier materials.”
4. Facilitating Drug Development
The columns are specifically designed to streamline workflow efficiencies, which aids in supporting clients as they develop new medications. Not only do they simplify bi-dimensional workflows for simultaneous analysis of titers and aggregates, but they are also easily integrable into new liquid chromatography-mass spectrometry setups. This capability fosters ongoing antibody sample analysis even in the absence of preliminary purification, leading to reduced operational timelines for projects.
Commitment to Innovation
Waters Corporation stands firmly committed to enhancing its analytical toolkits. This latest product plays a vital role in advancing biotherapy science, which ultimately benefits patients through accessible and effective treatments. The BioResolve columns are currently available in formats of 2.1 x 20 mm and 3.9 x 5 mm and can be ordered immediately on the company's website.
Conclusion
With over 65 years of expertise in analytical instruments and separation technologies, Waters Corporation leads the charge in ensuring the efficacy of drugs, safety of foods, and purity of water. Their dedication reflects a drive to foster innovation within life sciences that will pave the way for healthier lives around the globe. As the need for advanced biopharmaceuticals continues to grow, the introduction of the BioResolve Protein A Affinity Columns signifies a pivotal moment for researchers and biopharmaceutical companies alike.
Additional Resources
For more in-depth insights and specifications, visit Waters Corporation's official site.
- ---
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.